Compare Kimberly Clark Corp (KMB) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs ResMed Inc. — how do they compare? Kimberly Clark Corp trades at $97.59 (market cap $32.51B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: Kimberly Clark Corp and ResMed Inc. are close in size by market cap, and Kimberly Clark Corp pays the higher dividend (5.24%). Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and ResMed Inc. for 51 Days on average.
| KMB | RMD | |
|---|---|---|
Market Cap | $32.51B | $31.89B |
Volume | 6,139,913 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $275.96 |
52-Week Low | $93.05 | $182.82 |
Typical Hold Time | 93 Days | 51 Days |
Enterprise Value | $38.07B | $31.24B |
Dividend Yield | 5.24% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.74, up 1.31% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 11.79% net margins and 129.43% ROE, though Q2 2026 earnings missed expectations. Recent news highlights executive transitions and the pending Kenvue acquisition, while dividend sustainability questions emerge amid cash flow pressures. Analyst consensus remains cautious with 61% hold ratings despite a $117.25 price target suggesting 20% upside.
KMB presents a value opportunity with attractive dividend yield near 5%, but faces integration risks from the Kenvue deal and cash flow challenges. The stock's current discount to analyst targets offers potential upside if execution improves, though investors should monitor dividend coverage and acquisition integration closely given the bearish technical trend and mixed earnings performance.
ResMed (RMD) trades at $226.73, up 0.33% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming earnings report and positive analyst commentary on growth prospects.
The outlook is positive, driven by consistent earnings outperformance and a consensus price target of $242.70, implying upside. Key risks include competitive pressures and ongoing legal investigations. Institutional interest remains strong, with recent stake increases by funds. The stock's valuation metrics, such as a P/E of 21.74, appear reasonable given growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
